{Reference Type}: Journal Article
{Title}: Targeted Liposomal Drug Delivery: Overview of the Current Applications and Challenges.
{Author}: Gatto MS;Johnson MP;Najahi-Missaoui W;
{Journal}: Life (Basel)
{Volume}: 14
{Issue}: 6
{Year}: 2024 May 24
{Factor}: 3.251
{DOI}: 10.3390/life14060672
{Abstract}: In drug development, it is not uncommon that an active substance exhibits efficacy in vitro but lacks the ability to specifically reach its target in vivo. As a result, targeted drug delivery has become a primary focus in the pharmaceutical sciences. Since the approval of Doxil® in 1995, liposomes have emerged as a leading nanoparticle in targeted drug delivery. Their low immunogenicity, high versatility, and well-documented efficacy have led to their clinical use against a wide variety of diseases. That being said, every disease is accompanied by a unique set of physiological conditions, and each liposomal product must be formulated with this consideration. There are a multitude of different targeting techniques for liposomes that can be employed depending on the application. Passive techniques such as PEGylation or the enhanced permeation and retention effect can improve general pharmacokinetics, while active techniques such as conjugating targeting molecules to the liposome surface may bring even further specificity. This review aims to summarize the current strategies for targeted liposomes in the treatment of diseases.